Clinical TrialsAlkermes is advancing ALKS-2680 in Phase 2 trials for narcolepsy, representing a significant potential opportunity.
Sales PerformanceLybalvi's sales in 2Q saw revenues up 52% and total prescriptions up 44% year-over-year, driven by greater depth within existing prescribers and new prescriptions.
Stock BuybackAlkermes repurchased approximately $3.5 million shares for $85 million, enhancing the EPS growth profile.